Vaccine candidate against Chikungunya fever proves successful

June 12, 2014

A prophylactic vaccine candidate against Chikungunya fever, developed by the Austrian biotech company Themis Bioscience GmbH induces a significant neutralizing immune response and was also confirmed as safe. These are the major interim results of a phase 1 clinical study of the company's Chikungunya vaccine candidate that uses a standard anti-measles vaccine as a vector. The Chikungunya epidemic, currently raging through the Caribbean, illustrates the urgent necessity to develop an effective vaccine against the rapid spread of the disease in tropical regions, now also threatening the North American continent.

The Vienna-based biotech company Themis Bioscience GmbH today received the interim results of a phase 1 clinical study of its Chikungunya fever prophylactic vaccine. The study was carried out on 42 subjects in the Department of Clinical Pharmacology at the Vienna General Hospital, and confirms the expectations pinned on the vaccine: it not only proved to be well tolerated and safe, but also exhibited the required immune response in the form of neutralizing antibodies. Even the lowest doses used showed to be effective, and increasing doses led to respective stronger immune responses in the study subjects.

Commenting on the positive results, Themis founder and CEO, Dr. Erich Tauber, stated: "The confirmed tolerance, safety and show the suitability of our Themaxyn platform. This uses a standard anti-measles vaccine as a vector and constitutes the basis of our pipeline, comprising a Dengue fever and vaccine constructs for other rapidly spreading infectious diseases. The anti-measles vaccine has already proven itself a million times over, and hence the Themaxyn platform offers an excellent safety profile and clear advantages in terms of a validated, low-cost production process."

The Chikungunya epidemic, currently rampant in the Caribbean, shows that such a platform could soon be needed on a larger geographic scale. Having started in the Dominican Republic, it has already reached Haiti and fears are now growing that the disease could spread further to the USA, where isolated cases of Chikungunya have been observed in recent years. To date, no effective for this serious disease has been available and the US Centers for Disease Control and Prevention (CDC) are said to have warned hospitals throughout the country. Accordingly, representatives of the CDC are quoted in The Wall Street Journal as saying: "We are preparing for the potential introduction into the United States".

In light of such developments, the advantages of Themis' patent-protected Themaxyn platform are several fold, including a proven production process ensuring at a later stage the rapid supply on a large scale. Themis sees itself as a boutique biotech firm enabling such end objective, as Dr. Tauber explains: "Our expertise is in R&D. Therefore, we adapt the vector of the Themaxyn platform to new indications. In this context, we have already secured the rights for Dengue fever and we are contemplating a range of further indications. We aim to provide third parties with the rights to license, manufacture and market our development programs once the clinical proof of concept has been established, to then reinvest the proceeds in our research programs." Dr. Gerd Zettlmeissl, member of the supervisory board of Themis, adds: "The fully-patented Themaxyn platform and the focus on its R&D strengths make Themis one of the most effective biotech companies world-wide that develops vaccines against advancing tropical and other infectious diseases."

Explore further: US Virgin Islands confirms first chikungunya case (Update)

Related Stories

US Virgin Islands confirms first chikungunya case (Update)

June 11, 2014
A nasty mosquito-borne virus that has been spreading rapidly in the Caribbean has made its way to the U.S. Virgin Islands, authorities said Wednesday.

Mosquito-borne virus spreads rapidly in Haiti (Update)

May 13, 2014
A mosquito-borne virus that was detected for the first time in Haiti last week has quickly spread throughout the Caribbean nation, a health official said Tuesday.

Researchers develop prototype chikungunya vaccine

March 21, 2013
Wageningen University in the Netherlands has developed a prototype vaccine against chikungunya in a joint effort with the Erasmus Medical Centre and TI Pharma. This prototype may hopefully lead to the first working vaccine ...

Haiti offers treatment as virus outbreak surges

May 23, 2014
Haitian health authorities will distribute pain medication to clinics around the country amid a surge in suspected cases of a mosquito-borne virus that is new to the region, a government official said Friday.

Newly arrived virus spreads in Dominican Republic

April 29, 2014
Health officials in the Dominican Republic say a mosquito-borne virus has spread widely since making its first appearance in the country.

Guyana has first cases of virus new to region

May 28, 2014
At least two people have been sickened by the mosquito-borne chikungunya virus in Guyana in the first locally transmitted cases in the South American country, the health minister said Wednesday.

Recommended for you

Finish your antibiotics course? Maybe not, experts say

July 27, 2017
British disease experts on Thursday suggested doing away with the "incorrect" advice to always finish a course of antibiotics, saying the approach was fuelling the spread of drug resistance.

Co-infection with two common gut pathogens worsens malnutrition in mice

July 27, 2017
Two gut pathogens commonly found in malnourished children combine to worsen malnutrition and impair growth in laboratory mice, according to new research published in PLOS Pathogens.

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.